-transparent.png){kind=logo}
The development of immune checkpoint inhibitors (ICIs) constitutes a major therapeutic advance in the treatment of a number of malignancies [...].
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
May 2009,
Immunotherapy,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
January 2004,
Annual review of medicine,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
January 2015,
Cytotherapy,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
March 2016,
Oncoimmunology,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
October 1975,
Connecticut medicine,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
July 2020,
Clinical cancer research : an official journal of the American Association for Cancer Research,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
June 2018,
Translational oncology,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
April 2014,
The Journal of surgical research,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
December 2012,
Nihon rinsho. Japanese journal of clinical medicine,
Hortense de Saint Basile, and
Zineb Maaradji, and
Elizabeth Fabre
February 2018,
Current opinion in pediatrics,
